<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37594232</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><PubDate><Year>2023</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol Infect</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition.</ArticleTitle><Pagination><StartPage>e145</StartPage><MedlinePgn>e145</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0950268823001279</ELocationID><Abstract><AbstractText>Post COVID-19 condition (PCC) refers to persistent or recurring symptoms (&gt;8 weeks) occurring &#x2264;12 weeks following acute COVID-19. The objective of this systematic review was to assess the evidence on the risk of PCC with vaccination before or after COVID-19 or after developing PCC, and the safety of vaccination among those already experiencing PCC. A search was conducted up to 13 December 2022 and standard systematic review methodology was followed. Thirty-one observational studies were included. There is moderate confidence that two doses of vaccine given pre-infection reduced the odds of PCC (pooled OR (pOR) 0.67, 95% CI 0.60-0.74, I2 = 59.9%), but low confidence that one dose may not reduce the odds (pOR 0.64, 95% CI 0.31#x2013;1.31, I2 = 99.2%), and the evidence is very uncertain about the effect of three doses (pOR 0.45, 95% CI 0.10#x2013;1.99, I2 = 30.9%). One of three studies suggested vaccination shortly after COVID-19 may offer additional protection from developing PCC compared to unvaccinated individuals, but this evidence was very uncertain. For those with PCC, vaccination was not associated with worsening PCC symptoms (10 studies) and appears safe (3 studies), but it is unclear if vaccination may change established PCC symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Sydney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Risk Science Division, National Microbiology Laboratory, Public Health Agency of Canada, Guelph, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Medicine, University of Guelph, Guelph, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrin</LastName><ForeName>Tricia</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5514-1589</Identifier><AffiliationInfo><Affiliation>Public Health Risk Science Division, National Microbiology Laboratory, Public Health Agency of Canada, Guelph, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waddell</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Public Health Risk Science Division, National Microbiology Laboratory, Public Health Agency of Canada, Guelph, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035501" MajorTopicYN="N">Uncertainty</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare none.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37594232</ArticleId><ArticleId IdType="pmc">PMC10540166</ArticleId><ArticleId IdType="doi">10.1017/S0950268823001279</ArticleId><ArticleId IdType="pii">S0950268823001279</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (2021) A clinical case definition of post covid-19 condition by a delphi consensus. Geneva: World Health Organization, 6 October 2021. Report No: WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1.</Citation></Reference><Reference><Citation>Nalbandian A, et al. (2021) Post-acute covid-19 syndrome. Nature Medicine 27, 601&#x2013;615. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada. Post covid-19 condition (long covid). Available at https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html (accessed 14 September 2022).</Citation></Reference><Reference><Citation>Domingo FR, et al. (2021) Prevalence of long-term effects in individuals diagnosed with covid-19: An updated living systematic review. medRxiv. Epub June 3, 2021. 10.1101/2021.06.03.21258317</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.03.21258317</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn KL, et al.(2022) Understanding the post covid-19 condition (long covid) in adults and the expected burden for Ontario. The Ontario COVID-19 Science Advisory Table. Epub September 7, 2022. 10.47326/ocsat.2022.03.65.1.0</Citation><ArticleIdList><ArticleId IdType="doi">10.47326/ocsat.2022.03.65.1.0</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Coronavirus disease (covid-19): Post covid-19 condition. Available at https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition#:~:text=Symptoms%20of%20post%20COVID%2D19%20condition%20can%20persist%20from%20the,normal%20recovery%20process%20after%20illness (accessed 16 December 2021).</Citation></Reference><Reference><Citation>Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Covid-19 dashboard. Available at https://coronavirus.jhu.edu/map.html (accessed 20 November 2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P, Liu J and Liu M (2022) Effect of covid-19 vaccines on reducing the risk of long covid in the real world: A systematic review and meta-analysis. International Journal of Environmental Research and Public Health; 19, 12422. 10.3390/ijerph191912422</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912422</ArticleId><ArticleId IdType="pmc">PMC9566528</ArticleId><ArticleId IdType="pubmed">36231717</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, et al. (2022) Impact of covid-19 vaccination on the risk of developing long-covid and on existing long-covid symptoms: A systematic review. eClinicalMedicine 53, 101624. 10.1016/j.eclinm.2022.101624</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, et al. (2023) Effect of covid-19 vaccination on long covid: Systematic review. BMJ Medicine 2, e000385. 10.1136/bmjmed-2022-000385</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, et al. (2022) The effectiveness of coronavirus disease 2019 (covid-19) vaccine in the prevention of post&#x2013;covid-19 conditions: A systematic literature review and meta-analysis. Antimicrobial Stewardship &amp; Healthcare Epidemiology 2, e192. 10.1017/ash.2022.336</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.336</ArticleId><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, et al. (2009) The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Journal of Clinical Epidemiology 62, e1&#x2013;e34. 10.1016/j.jclinepi.2009.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.006</ArticleId><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, et al. Cochrane handbook for systematic reviews of interventions version 6.3: Cochrane. Available at www.training.cochrane.org/handbook (accessed September 2022).</Citation></Reference><Reference><Citation>Corrin T, et al. (2023) Covid-19 literature surveillance&#x2014;A framework to manage the literature and support evidence-based decision-making on a rapidly evolving public health topic. Canada Communicable Disease Report 49, 5&#x2013;9. 10.14745/ccdr.v49i01a02</Citation><ArticleIdList><ArticleId IdType="doi">10.14745/ccdr.v49i01a02</ArticleId><ArticleId IdType="pmc">PMC9902036</ArticleId><ArticleId IdType="pubmed">36815866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauernfeind S and Schmidt B (2022) The value of covid-19 vaccination in the context of long-covid. Die Innere Medizin; 63, 840&#x2013;850. 10.1007/s00108-022-01368-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00108-022-01368-y</ArticleId><ArticleId IdType="pmc">PMC9261894</ArticleId><ArticleId IdType="pubmed">35925072</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumtaz A, et al. (2022) Covid-19 vaccine and long covid: A scoping review. Life 12, 1066. 10.3390/life12071066</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12071066</ArticleId><ArticleId IdType="pmc">PMC9324565</ArticleId><ArticleId IdType="pubmed">35888154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjaji N, et al. (2022) 16 months follow up of patients&#x2019; behavior and mild covid-19 patterns in a large cohort of cancer patients during the pandemic. Frontiers in Oncology 12, 901426. 10.3389/fonc.2022.901426</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.901426</ArticleId><ArticleId IdType="pmc">PMC9209649</ArticleId><ArticleId IdType="pubmed">35747798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, et al. (2022) The protective effect of coronavirus disease 2019 (covid-19) vaccination on postacute sequelae of covid-19: A multicenter study from a large national health research network. Open Forum Infectious Diseases 9, ofac228. 10.1093/ofid/ofac228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, et al. The Newcastle-Ottawa Scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. Available at https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 14 September 2022).</Citation></Reference><Reference><Citation>Sterne JA, et al. (2016) Robins-i: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919. 10.1136/bmj.i4919</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro CM, et al. (2020) Exposure to endocrine-disrupting chemicals and anthropometric measures of obesity: A systematic review and meta-analysis. BMJ Open 10, e033509. 10.1136/bmjopen-2019-033509</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-033509</ArticleId><ArticleId IdType="pmc">PMC7311014</ArticleId><ArticleId IdType="pubmed">32565448</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J and Yu KF (1998) What&#x2019;s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. Journal of the American Medical Association 280, 1690&#x2013;1691. 10.1001/jama.280.19.1690</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.280.19.1690</ArticleId><ArticleId IdType="pubmed">9832001</ArticleId></ArticleIdList></Reference><Reference><Citation>Carazo S, et al. (2022) Physical, psychological and cognitive profile of post-covid condition in healthcare workers, Quebec, Canada. Open Forum Infectious Diseases 9, ofac386. 10.1093/ofid/ofac386</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac386</ArticleId><ArticleId IdType="pmc">PMC9379818</ArticleId><ArticleId IdType="pubmed">35983264</ArticleId></ArticleIdList></Reference><Reference><Citation>George A, Stead TS and Ganti L (2020) What&#x2019;s the risk: Differentiating risk ratios, odds ratios, and hazard ratios? Cureus 12, e10047. 10.7759/cureus.10047.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.10047</ArticleId><ArticleId IdType="pmc">PMC7515812</ArticleId><ArticleId IdType="pubmed">32983737</ArticleId></ArticleIdList></Reference><Reference><Citation>IntHout J, Ioannidis JPA and Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard Dersimonian-Laird method. BMC Medical Research Methodology 14, 25. 10.1186/1471-2288-14-25</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-25</ArticleId><ArticleId IdType="pmc">PMC4015721</ArticleId><ArticleId IdType="pubmed">24548571</ArticleId></ArticleIdList></Reference><Reference><Citation>IntHout J, et al. (2016) Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 6, e010247. 10.1136/bmjopen-2015-010247</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2015-010247</ArticleId><ArticleId IdType="pmc">PMC4947751</ArticleId><ArticleId IdType="pubmed">27406637</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann H, et al. (2011) The grade approach and Bradford hill&#x2019;s criteria for causation. Journal of Epidemiology and Community Health 65, 392. 10.1136/jech.2010.119933</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.2010.119933</ArticleId><ArticleId IdType="pubmed">20947872</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B and Xie Y (2022) Long covid after breakthrough Sars-Cov-2 infection. Nature Medicine 28, 1461&#x2013;1467. 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, et al. (2022a) Risk of long covid in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: Community-based, matched cohort study. Open Forum Infectious Diseases 9, ofac464. 10.1093/ofid/ofac464</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, et al. (2023) Post covid-19 condition after wildtype, delta, and omicron Sars-Cov-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PlosOne 18, e0281429. 10.1371/journal.pone.0281429</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281429</ArticleId><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock D, et al. (2023) Long covid risk and pre-covid vaccination in an EHR-based cohort study from the recover program. Nature Communications 14, 2914. 10.1038/s41467-023-38388-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38388-7</ArticleId><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Emecen AN, et al. (2022) The presence of symptoms within 6 months after covid-19: A single-center longitudinal study. Irish Journal of Medical Science 192, 741&#x2013;750. 10.1007/s11845-022-03072-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-03072-0</ArticleId><ArticleId IdType="pmc">PMC9205653</ArticleId><ArticleId IdType="pubmed">35715663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, et al. (2022) Outcomes among confirmed cases and a matched comparison group in the long-covid in Scotland study. Nature Communications 13, 5663. 10.1038/s41467-022-33415-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, et al. (2022) Rates and factors associated with documentation of diagnostic codes for long covid in the national veterans affairs health care system. JAMA Network Open 5, E2224359. 10.1001/jamanetworkopen.2022.24359</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.24359</ArticleId><ArticleId IdType="pmc">PMC9338411</ArticleId><ArticleId IdType="pubmed">35904783</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, et al. (2023) A cohort study of post-covid-19 condition across the beta, delta, and omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. International Journal of Infectious Diseases 128, 102&#x2013;111. 10.1016/j.ijid.2022.12.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.12.036</ArticleId><ArticleId IdType="pmc">PMC9800016</ArticleId><ArticleId IdType="pubmed">36587841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento TC, et al. (2023) Vaccination status and long covid symptoms in patients discharged from hospital. Scientific Reports 13, 2481. 10.1038/s41598-023-28839-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-28839-y</ArticleId><ArticleId IdType="pmc">PMC9922040</ArticleId><ArticleId IdType="pubmed">36774419</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MA, Luginbuhl R and Parker R.(2021) Reduced incidence of long-covid symptoms related to administration of covid-19 vaccines both before covid-19 diagnosis and up to 12 weeks after. medRxiv. Epub November 17, 2021. 10.1101/2021.11.17.21263608</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q and Harrison PJ (2022) Six-month sequelae of post-vaccination Sars-Cov-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain, Behavior, and Immunity 103, 154&#x2013;162. 10.1016/j.bbi.2022.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Agency of Canada Covid-19: Longer-term symptoms among Canadian Adults - Second Report. Ottawa, Canada: Public Health Agency of Canada, March 24, 2023. Report No. Available at https://health-infobase.canada.ca/covid-19/post-covid-condition/spring-2023-report.html (accessed 17 April 2023).</Citation></Reference><Reference><Citation>Spiliopoulos L, et al. (2022) Post-acute symptoms four months after Sars-Cov-2 infection during the omicron period: A nationwide Danish questionnaire study. medRxiv. Epub October 12, 2022. 10.1101/2022.10.12.22280990</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.12.22280990</ArticleId><ArticleId IdType="pmc">PMC11299024</ArticleId><ArticleId IdType="pubmed">37981717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert CR, et al. (2023) Post-acute sequelae after severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) infection by viral variant and vaccination status: A multicenter cross-sectional study. Clinical Infectious Diseases:ciad143. 10.1093/cid/ciad143</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad143</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, et al. (2022b) Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. British Medical Journal 377, e069676. 10.1136/bmj-2021-069676</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Cirarda M, et al. (2023) Multimodal neuroimaging in post-covid syndrome and correlation with cognition. Brain 146, 2142&#x2013;2152. 10.1093/brain/awac384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac384</ArticleId><ArticleId IdType="pmc">PMC9620345</ArticleId><ArticleId IdType="pubmed">36288544</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, et al.(2021) Are vaccines safe in patients with long covid? A prospective observational study. medRxiv. Epub March 11, 2021. 10.1101/2021.03.11.21253225</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, et al.(2023) Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: Target trial emulation based on compare e-cohort. BMJ Medicine 2, e000229. 10.1136/bmjmed-2022-000229</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000229</ArticleId><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E, et al. (2022) The effect of Sars-Cov-2 vaccination on post-acute sequelae of covid-19 (PASC): A prospective cohort study. Vaccine 40, 4424&#x2013;4431. 10.1016/j.vaccine.2022.05.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky JP, et al. (2022) Association of vaccination with the persistence of post-covid symptoms. Journal of General Internal Medicine 37, 1748&#x2013;1753. 10.1007/s11606-022-07465-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07465-w</ArticleId><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, et al. (2022) Post-covid-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clinical Microbiology and Infection 28, 1140&#x2013;1148. 10.1016/j.cmi.2022.03.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC8940723</ArticleId><ArticleId IdType="pubmed">35339673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, et al. (2022) Symptoms after covid-19 vaccination in patients with post-acute sequelae of Sars-Cov-2. Journal of General Internal Medicine 37, 1585&#x2013;1588. 10.1007/s11606-022-07443-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07443-2</ArticleId><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>Suyanto S, et al. (2022) The quality of life of coronavirus disease survivors living in rural and urban area of Riau province, Indonesia. Infectious Disease Reports 14, 33&#x2013;42. 10.3390/idr14010005</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr14010005</ArticleId><ArticleId IdType="pmc">PMC8788287</ArticleId><ArticleId IdType="pubmed">35076531</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain WD, et al. (2022) The impact of covid vaccination on symptoms of long covid: An international survey of people with lived experience of long covid. Vaccine 10, 652. 10.3390/vaccines10050652</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna B, et al.(2022) Spontaneous, persistent t-cell dependent ifn-&#x3b3; release in patients who progress to long covid. Research Square. Epub November 21, 2022. 10.21203/rs.3.rs-2034285/v2</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-2034285/v2</ArticleId><ArticleId IdType="pmc">PMC10881041</ArticleId><ArticleId IdType="pubmed">38381822</ArticleId></ArticleIdList></Reference><Reference><Citation>Raw RK, et al. (2021) Previous covid-19 infection, but not long-covid, is associated with increased adverse events following bnt162b2/pfizer vaccination. Journal of Infection 83, 381&#x2013;412. 10.1016/j.jinf.2021.05.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.05.035</ArticleId><ArticleId IdType="pmc">PMC8164507</ArticleId><ArticleId IdType="pubmed">34062184</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaber TAZK, et al. (2021) Are mRNA covid 19 vaccines safe in long covid patients? A health care workers perspective. British Journal of Medical Practitioners 14, a008.</Citation></Reference><Reference><Citation>Bowe B, Xie Y and Al-Aly Z (2022) Acute and postacute sequelae associated with Sars-Cov-2 reinfection. Nature Medicine; 28, 2398&#x2013;2405. 10.1038/s41591-022-02051-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>